J1 Beach partners with D-Marin to Launch Anchorage Experience
This new arrival experience is made possible through the launch of the J1 Beach Anchorage Zone, allowing private yacht owners and charter guests to anchor offshore and be seamlessly welcomed ashore. Operated by D-Marin – who manage five premium marinas across Dubai – this service enhances access while upholding world-class standards of comfort and hospitality.
Situated along the vibrant coastline, J1 Beach is home to 13 celebrated licensed restaurants and beach clubs, each bringing distinct flavours from across the globe – whether it's the refined tastes of the French Riviera, the vibrancy of Tulum, or the flair of New York. The destination blends sun-drenched relaxation with culinary excellence, setting a new benchmark for day-to-night dining in Dubai.
Among the standout venues is Kaimana Beach, a Pan Asian cuisine concept with an Island flair. With its dreamy tropical atmosphere, the restaurant delivers bold Pan Asian flavours through signature dishes like Oxtail Siamin Dumplings, Saikyo Miso Cod Skewers, Hamachi Truffle with crispy potato shavings, and an island-inspired Beef Cheek Loco Moco. While the poolside area caters exclusively to adults, the beach facilities welcome families, ensuring the space offers something for every guest.
For those looking to charter a yacht, a variety of premium providers are available – including BENO, a luxury mobility brand renowned for its expertly designed superyachts and tailored onboard experiences. With vessels like the 115-foot Santorini – combining advanced marine technology with elegant finishes – the journey to J1 Beach becomes as special as the destination itself.
More than just a place to dine, J1 Beach unites culinary excellence, beachfront luxury, and world-class service in one unforgettable experience. From poolside lounging to energetic nightlife, it's a destination where guests can explore, unwind, and savour life with sophistication and ease.
News Source: Havas Red
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
an hour ago
- Zawya
Minapharm's majority shareholder Triquera raises capital through minority stake investment from Admaius Capital Partners
Cairo, Egypt - Admaius Capital Partners ('Admaius'), an Africa-focused private equity investor, and Triquera B.V. ('Triquera'), the majority shareholder in Minapharm Pharmaceuticals and Chemical Industries S.A.E. ('Minapharm'), a leading biopharmaceutical company in the Middle East and Africa and a global provider of proprietary technologies to leading biopharma players, today announced a strategic partnership following Admaius' investment in Triquera B.V. For over two decades, Minapharm has established a robust biopharmaceutical platform that combines world-class R&D with end-to-end manufacturing capabilities for complex genetically engineered therapeutic recombinant proteins and viral vectors as well as small molecules with advanced galenic formulations, operating across facilities in Cairo and Berlin. Today, Minapharm operates the largest biological drug substance and drug product facilities in the Middle East and Africa. Through its international subsidiaries, Minapharm licenses out proprietary technologies in the fields of monoclonal antibodies, vaccines, and cell and gene therapies. These technologies enable the development and production of advanced biologics that address critical unmet medical needs globally and have been incorporated into FDA-approved products, underscoring their clinical relevance and global impact. Together, Triquera and Admaius will focus on accelerating the development and production of complex genetically engineered therapies, while expanding access to high-quality, affordable recombinant proteins by investing in innovation and scaling distribution to better serve patients across underserved markets in Africa and the Middle East. In parallel, the partnership will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm's growth in the biotech sector. This partnership reflects a shared commitment to advancing healthcare equity through innovation and aligns closely with Admaius' broader strategy of supporting mission-driven businesses and management teams in high-impact sectors across the African continent. Zilla Capital acted as the sole financial advisor to Triquera B.V. and the existing shareholders. Matouk Bassiouny served as legal counsel to Triquera B.V. and the existing shareholders. Admaius Capital Partners was advised by White and Case LLP as legal counsel and by Arthur D. Little as commercial advisor. Commenting on the investment: Dr. Wafik Bardissi, Chairman and CEO of Minapharm, said: "This partnership reflects the accelerating momentum of Minapharm's growth as we extend our leadership in biotherapeutics, cell and gene therapies, and proprietary platform technologies. With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations." Marlon Chigwende, Managing Partner of Admaius, said: 'This is a landmark transaction. The founding families have built a unique asset on the African and European continents that combines scale, growth and impact to fight cancer and other awful diseases. We are pleased to be able to partner with Triquera, Dr. Wafik and Dr. Shaheer and will help to internationalize and grow the business further.' Ahmed Rady, Managing Director of Admaius, said: 'At Admaius, we back exceptional management teams—and the team behind Minapharm is as impressive as the science, technology, and capabilities they've built across Cairo and Berlin. This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence. We're excited to support Minapharm in taking this next big step and look forward to working closely with the management team.' Dr. Shaheer Bardissi, Co-CEO of Minapharm, added: 'This strategic collaboration with Admaius will accelerate and scale Minapharm's vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy as well as advanced therapy medicinal products, for the benefit of the broader biopharmaceutical industry.' Contacts For more information, please contact: Minapharm Christina Azmy cazmy@ (+2) (02) 24143170 Admaius Hannah Gilkes Phone number: +44 7515 958912
Zawya
3 days ago
- Zawya
Ambassador GAO Wenqi Visits Chinese-Invested Enterprises in Rwanda
On July 25, Ambassador GAO Wenqi visited the C&D Products Group. The company executives gave a briefing on the company's production, operations, and development, as well as the working and living conditions of its employees. Ambassador GAO encouraged the company to adhere to safe production and compliant operation, and take good care of its employees, so as to actively fulfill its social responsibilities and set up a good image for Chinese enterprises. He also asked the company to actively take part in and contribute to Rwanda's economic and social development, and promote China-Rwanda relations. Specializing in apparel manufacturing and export, C&D was established in Rwanda in 2019. It has created over 7,000 jobs for local communities. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Rwanda.
Emirates 24/7
6 days ago
- Emirates 24/7
AstraZeneca plans to invest $50 billion in US by 2030
AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas. Follow Emirates 24|7 on Google News.
